Home / Public Antibody Sequence Database / Atezolizumab PUBLIC ANTIBODY SEQUENCE · PSC-PDL1-002 Atezolizumab antibody sequence PD-L1 / CD274 · CD274
A commonly used reference sequence for PD-L1 expression, receptor-occupancy and immune-checkpoint blockade research.
PD-L1 CD274 B7-H1 Whole mAb IgG1
Project planning Technical review required Scope and timing are confirmed only after the sequence, construct, labeling plan and requested deliverables have been assessed.
Ask about expression and labeling VH · Heavy chain variable region 118 aa
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSSVL · Light chain variable region 107 aa
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKRecord information
Antibody name Atezolizumab
Target PD-L1 / CD274
Gene symbol CD274
Molecular format Whole mAb
Heavy-chain isotype IgG1
Light-chain type Kappa
Project code PSC-PDL1-002 Alternate names Tecentriq · MPDL3280A · RG7446
RESEARCH USE Suggested research applications PD-L1 binding detection Competitive blocking Flow cytometry Tumor-cell phenotyping FLUORESCENT OPTIONS Suggested starting labels SF488 SF594 PE APC
Dye selection can be adjusted for instrument lasers, co-expression intensity and panel design. Final selection is confirmed during project assessment.
DELIVERABLE Optional project scope Sequence review and construct design Recombinant expression and purification Fluorescent conjugation and free-dye removal Concentration, appearance and agreed basic quality checks START FROM THIS SEQUENCE Start a project from this public sequence Submit the intended antibody format, scale, fluorophore and application. We will first confirm the technical route and delivery boundaries.
Use and intellectual-property boundaries A public sequence does not imply freedom to operate or a commercial license. This record supports research search and project discussion. Customers should complete patent, licensing and freedom-to-operate assessment for the intended use. Antibody names and related trademarks belong to their respective owners; this page does not imply affiliation with or authorization from the originator company.